# A Novel Germline MUTYH Mutation (p.W156∗) in High-Grade Astrocytoma, IDH Mutant

**Authors:** Lulu Zhang, Shaoyan Xi, Lei Yuan, Ziteng Li, Xiaoyun Liu, Jiamei Gu, Shuo Li, Liyun Huang, Wanming Hu, Lingyi Fu

PMC · DOI: 10.1155/humu/4321571 · Human Mutation · 2025-05-28

## TL;DR

A new MUTYH gene mutation is linked to high-grade brain tumors in young patients, suggesting a genetic predisposition to these cancers.

## Contribution

The study identifies a novel pathogenic MUTYH mutation (p.W156∗) in high-grade astrocytoma patients with IDH mutations.

## Key findings

- Patients with the MUTYH mutation had microsatellite stability and low tumor mutation burden.
- The mutation was associated with an immunosuppressive tumor environment and potential for targeted therapy via MET amplification.
- Germline MUTYH mutations were found in 11 CNS tumor cases, primarily in pediatric and young adult populations.

## Abstract

Germline mutations in the DNA repair gene E. coli MutY homolog (MUTYH) are established predisposing factors for colorectal polyposis, colorectal carcinoma, and various extracolonic malignancies. Nevertheless, the association between MUTYH mutations and central nervous system (CNS) tumorigenesis remains poorly characterized. In this study, we reported the first identification of a novel c.467G > A (p.W156∗) MUTYH variant in two patients with high-grade astrocytoma, IDH mutant, which was classified as pathogenic. Histopathological evaluation revealed tumor morphologies consistent with either diffuse glioma or giant cell glioblastoma. Comparative analysis with mismatch repair (MMR)–deficient tumors demonstrated that patients carrying MUTYH mutations exhibited microsatellite stability, relatively low tumor mutation burden (TMB), and an immunosuppressive microenvironment, indicating difficulties in benefiting from immunotherapy. Fortunately, gain of Chromosome 7, in association with amplification of the MET gene, was detected, underscoring the possible application of targeted drugs. Integrating previous studies, we summarized germline MUTYH mutations in 11 cases of high-grade neuroepithelial tumors (eight gliomas and three medulloblastomas). This cohort demonstrated a predilection for pediatric and young adult populations without significant gender predominance. Our findings suggested a potential association between germline MUTYH mutations and CNS tumor susceptibility.

## Linked entities

- **Genes:** MUTYH (mutY DNA glycosylase) [NCBI Gene 4595], MET (MET proto-oncogene, receptor tyrosine kinase) [NCBI Gene 4233]
- **Diseases:** colorectal carcinoma (MONDO:0024331)

## Full-text entities

- **Genes:** MUTYH (mutY DNA glycosylase) [NCBI Gene 4595] {aka MYH}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}
- **Diseases:** glioblastoma (MESH:D005909), medulloblastomas (MESH:D008527), neuroepithelial tumors (MESH:D018302), colorectal carcinoma (MESH:D015179), extracolonic malignancies (MESH:D009369), glioma (MESH:D005910)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** c.467G > A

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12136872/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12136872/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12136872/full.md

---
Source: https://tomesphere.com/paper/PMC12136872